{{Rsnum
|rsid=1504771
|Gene=CSMD1
|Chromosome=8
|position=4242629
|Orientation=minus
|GMAF=0.4362
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=CSMD1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 33.6 | 45.1 | 21.2
| HCB | 22.8 | 46.3 | 30.9
| JPT | 16.7 | 49.1 | 34.3
| YRI | 7.8 | 36.9 | 55.3
| ASW | 7.5 | 39.6 | 52.8
| CHB | 22.8 | 46.3 | 30.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 7.3 | 39.6 | 53.1
| LWK | 0.0 | 0.0 | 0.0
| MEX | 26.3 | 50.9 | 22.8
| MKK | 11.8 | 43.1 | 45.1
| TSI | 30.0 | 44.0 | 26.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1504771
|Name_s=
|Gene_s=CSMD1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109369
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1504771
|overall_frequency_n=54
|overall_frequency_d=128
|overall_frequency=0.421875
|n_genomes=34
|n_genomes_annotated=0
|n_haplomes=44
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}